A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of the Rivastigmine Patch in Japanese Patients with Alzheimer’s Disease

By  

Dementia and Geriatric Cognitive Disorders Extra, Vol. 1, Iss. 1, 2011-06 ,pp. : 163-179

Karger

Access to resources Recommend Favorite

Randomized, Double-Blind, Parallel-Group, 48-Week Study for Efficacy and Safety of a Higher-Dose Rivastigmine Patch (15 vs. 10 cm2) in Alzheimer’s Disease

By  

Dementia and Geriatric Cognitive Disorders, Vol. 33, Iss. 5, 2012-07 ,pp. : 341-353

Karger

Access to resources Recommend Favorite

A 52-Week Study of the Efficacy of Rivastigmine in Patients with Mild to Moderately Severe Alzheimer’s Disease

By  

European Neurology, Vol. 44, Iss. 4, 2000-11 ,pp. : 236-241

Karger

Access to resources Recommend Favorite

An eight-week, multicenter, randomized, double-blind study to evaluate the efficacy and tolerability of fixed-dose amlodipine/benazepril combination in comparison with amlodipine as first-line therapy in Chinese patients with mild to moderate hypertension

By Ueng Kwo-Chang   Lin Lung-Chun   Voon Wen-Chol   Lin Ming-Cheng   Liu Yen-Bin   Su Ho-Ming   Chang Po-Yuan   Lin Tsung-Hsien   Chen Wei-Liang   Wu Chau-Chung   Lai Wen-Ter   Lin Chung-Sheng  

Blood Pressure, Vol. 17, Iss. 1, 2008-06 ,pp. : 24-31

Informa Healthcare

Access to resources Recommend Favorite

A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome

By Nyhlin H.   Bang C.   Elsborg L.   Silvennoinen J.   Holme I.   Rüegg P.   Jones J.   Wagner A.  

Scandinavian Journal of Gastroenterology, Vol. 39, Iss. 2, 2004-02 ,pp. : 119-126

Informa Healthcare

Access to resources Recommend Favorite